Shots:
- GSK has entered an exclusive strategic collaboration with Sino Biopharmaceutical, via its subsidiary CTTQ, to support the launch & commercialization of bepirovirsen (under NMPA’s priority review) in mainland China
- CTTQ will manage importation, distribution, hospital access, and promotional & non-promotional activities in China under a 5.5yr. supply deal with GSK
- On the other hand, GSK will remain market authorisation holder, & handle regulatory, quality, PV, & global medical strategy responsibilities, while also reviewing select early-stage SBP pipeline assets for ex-China collaborations
Ref: GSK | Image: GSK & Sino | Press Release
Related News: GSK Partners with Halozyme to Develop SC Formulation of Multiple Oncology Drugs
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
